ESMO 2016: Spectacular data in NSCLC, but many questions remainNew immunotherapies are producing impressive results in lung cancer Share XESMO 2016: Spectacular data in NSCLC, but many questions remainhttps://pharmaphorum.com/articles/esmo-2016-spectacular-immunotherapy-data-lung-cancer-many-questions-remain/
Spotlight on – The Future of Oncology Clinical TrialsWe present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with Share XSpotlight on – The Future of Oncology Clinical Trialshttps://pharmaphorum.com/views-and-analysis/future-oncology-focus/